Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
271 hedge funds and large institutions have $6.72B invested in Acceleron Pharma in 2021 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 91 increasing their positions, 83 reducing their positions, and 28 closing their positions.
54% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 28
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
6% more funds holding
Funds holding: 256 → 271 (+15)
10% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 83
8% less capital invested
Capital invested by funds: $7.3B → $6.72B (-$584M)
43% less call options, than puts
Call options by funds: $24.9M | Put options by funds: $43.9M
Top Buyers
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$116M |
| 2 |
Alkeon Capital Management
New York
|
-$59.7M |
| 3 |
Goldman Sachs
New York
|
-$30.2M |
| 4 |
BlackRock
New York
|
-$28.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$21M |
XLRN Hedge Fund Activity: Q2 2021 in Review
271 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q2 2021, worth a combined $6.72B — down 8% from $7.3B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new XLRN positions and 28 closed out — a net gain of 15 holders — while 91 added to existing stakes and 83 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $55.4M. The largest seller was Fidelity Investments, cutting an estimated $116M.
- 271 institutional investors held Acceleron Pharma (XLRN) as of Q2 2021, up from 256 in Q1 2021.
- Funds reported $6.72B of Acceleron Pharma stock for Q2 2021, down 8% quarter-over-quarter.
- 43 funds opened new Acceleron Pharma positions in Q2 2021 and 28 closed out, a net change of +15 holders.
- The largest Acceleron Pharma buyer in Q2 2021 was Assenagon Asset Management, an estimated $55.4M added.
- The largest Acceleron Pharma seller in Q2 2021 was Fidelity Investments, an estimated $116M sold.
Based on aggregated 13F filings for Q2 2021.